Please login to the form below

Not currently logged in
Email:
Password:

EGFR-mutation

This page shows the latest EGFR-mutation news and features for those working in and with pharma, biotech and healthcare.

AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain

AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain

Results showing EGFR-inhibitor improves outcomes in adjuvant setting released at ESMO 2020 virtual congress. ... Approximately a quarter of global lung cancer cases are EGFR-mutated, although in Asia the rate can climb to over 40% of new cases.

Latest news

More from news
Approximately 2 fully matching, plus 50 partially matching documents found.

Latest Intelligence

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    There is a good reason why Tagrisso was chosen for the fast track – the drug is for patients with epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung ... The EGFR mutation is particularly prevalent in Asian populations

  • Harnessing complexity Harnessing complexity

    While more established methodologies still dominate, Next Generation Sequencing is starting to make an impact in the Oncology CDx world, as this breakdown of methodologies used for EGFR mutation testing in

  • Transforming times at AstraZeneca Transforming times at AstraZeneca

    It is a particularly pressing matter for AZ considering the company has several personalised medicines on market or in development, including Iressa (gefitinib) to treat lung cancer patients with a mutation ... in the EGFR-TK gene and Lynparza, which is

  • Diagnostics are rising up the pharma value chain Diagnostics are rising up the pharma value chain

    lung cancer, which was backed together with Roche Diagnostics' cobas EGFR Mutation Test. ... He adds: “What do we do when a person says they have a mutation of this type of cancer and there seems to be a drug.

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    If approved, the drug would complement AZ's other NSCLC drug, Iressa, which is approved in NSCLC patients with the EGFR mutation. ... Another development is AZD9291 – a drug which addresses the T790M mutation, which is a key resistance mechanism to

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
VISFO

A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....